Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-02-14 4:17 pm Purchase | 2021-12-31 | 13G | Rhythm Pharmaceuticals, Inc. RYTM | BAKER BROS. ADVISORS LP | 3,863,239 7.700% | 1,548,366 (+66.89%) | Filing History |
| 2022-02-14 4:16 pm Purchase | 2021-12-31 | 13G | Otonomy, Inc. OTIC | BAKER BROS. ADVISORS LP | 7,844,692 13.800% | 624,618 (+8.65%) | Filing History |
| 2022-02-14 4:16 pm Purchase | 2021-12-31 | 13G | Zymeworks Inc. ZYME | BAKER BROS. ADVISORS LP | 4,977,296 9.990% | 67,486 (+1.37%) | Filing History |
| 2022-02-14 4:16 pm Purchase | 2021-12-31 | 13G | Mereo BioPharma Group plc MREO | BAKER BROS. ADVISORS LP | 64,917,601 9.990% | 25,285,672 (+63.80%) | Filing History |
| 2022-02-14 4:16 pm Purchase | 2021-12-31 | 13G | Verastem, Inc. VSTM | BAKER BROS. ADVISORS LP | 1,790,969 11.800% | 233,828 (+15.02%) | Filing History |
| 2022-02-14 4:15 pm Purchase | 2021-12-31 | 13G | Surrozen, Inc. SRZN | BAKER BROS. ADVISORS LP | 222,222 9.300% | 222,222 (New Position) | Filing History |
| 2022-02-14 4:15 pm Purchase | 2021-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX | BAKER BROS. ADVISORS LP | 18,464,744 9.950% | 285,863 (+1.57%) | Filing History |
| 2022-02-14 4:15 pm Sale | 2021-12-31 | 13G | Opthea Limited OPT | BAKER BROS. ADVISORS LP | 26,427,521 7.500% | -7,535,719 (-22.19%) | Filing History |
| 2022-02-14 4:15 pm Purchase | 2021-12-31 | 13G | Nurix Therapeutics, Inc. NRIX | BAKER BROS. ADVISORS LP | 2,454,082 5.500% | 2,454,082 (New Position) | Filing History |
| 2022-02-14 4:15 pm Purchase | 2021-12-31 | 13G | Heron Therapeutics, Inc. HRTX | BAKER BROS. ADVISORS LP | 8,131,678 8.000% | 66,846 (+0.83%) | Filing History |
| 2022-02-14 4:14 pm Purchase | 2021-12-31 | 13G | Immatics N.V. IMTX | BAKER BROS. ADVISORS LP | 4,423,731 7.000% | 4,423,731 (New Position) | Filing History |
| 2022-02-14 4:14 pm Purchase | 2021-12-31 | 13G | Global Blood Therapeutics, Inc. GBT | BAKER BROS. ADVISORS LP | 3,314,765 5.100% | 3,314,765 (New Position) | Filing History |
| 2022-02-14 4:14 pm Purchase | 2021-12-31 | 13G | Aerovate Therapeutics, Inc. AVTE | BAKER BROS. ADVISORS LP | 1,831,789 7.500% | 1,831,789 (New Position) | Filing History |
| 2022-02-14 4:13 pm Purchase | 2021-12-31 | 13G | Ascendis Pharma A/S ASND | BAKER BROS. ADVISORS LP | 4,541,604 8.000% | 1,001,334 (+28.28%) | Filing History |
| 2022-02-14 4:13 pm Sale | 2021-12-31 | 13G | Amarin Corporation plc AMRN | BAKER BROS. ADVISORS LP | 21,293,177 5.400% | -13,326,880 (-38.49%) | Filing History |
| 2022-02-14 4:13 pm Purchase | 2021-12-31 | 13G | Altimmune, Inc. ALT | BAKER BROS. ADVISORS LP | 1,941,604 4.800% | 57,153 (+3.03%) | Filing History |
| 2022-02-14 4:13 pm Purchase | 2021-12-31 | 13G | Aligos Therapeutics, Inc. ALGS | BAKER BROS. ADVISORS LP | 83,056 5.300% | 83,056 (New Position) | Filing History |
| 2022-02-14 4:12 pm Purchase | 2021-12-31 | 13G | Achilles Therapeutics plc ACHL | BAKER BROS. ADVISORS LP | 4,039,480 9.990% | 4,039,480 (New Position) | Filing History |
| 2022-02-10 5:03 pm Purchase | 2022-02-09 | 13D | Aeglea BioTherapeutics, Inc. AGLE | BAKER BROS. ADVISORS LP | 201,779 9.900% | 5,732 (+2.92%) | Filing History |
| 2022-01-31 5:10 pm Purchase | 2022-01-27 | 13D | Kodiak Sciences Inc. KOD | BAKER BROS. ADVISORS LP | 15,566,068 30.100% | 848,776 (+5.77%) | Filing History |